Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Purchased by Klingenstein Fields & Co. LP

Klingenstein Fields & Co. LP grew its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 0.2% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 76,315 shares of the medical research company’s stock after buying an additional 135 shares during the period. Thermo Fisher Scientific accounts for approximately 1.9% of Klingenstein Fields & Co. LP’s holdings, making the stock its 14th biggest holding. Klingenstein Fields & Co. LP’s holdings in Thermo Fisher Scientific were worth $47,206,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in TMO. BDF Gestion acquired a new position in shares of Thermo Fisher Scientific in the 2nd quarter valued at about $6,368,000. Nisa Investment Advisors LLC lifted its position in Thermo Fisher Scientific by 6.2% during the third quarter. Nisa Investment Advisors LLC now owns 140,708 shares of the medical research company’s stock valued at $87,093,000 after buying an additional 8,180 shares in the last quarter. Lord Abbett & CO. LLC increased its position in shares of Thermo Fisher Scientific by 1.9% in the first quarter. Lord Abbett & CO. LLC now owns 78,247 shares of the medical research company’s stock worth $45,478,000 after acquiring an additional 1,480 shares in the last quarter. Advisors Capital Management LLC raised its stake in shares of Thermo Fisher Scientific by 5.8% in the 1st quarter. Advisors Capital Management LLC now owns 111,169 shares of the medical research company’s stock valued at $64,613,000 after acquiring an additional 6,089 shares during the period. Finally, Seven Eight Capital LP purchased a new stake in Thermo Fisher Scientific during the 1st quarter worth $1,161,000. 89.23% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In related news, EVP Gianluca Pettiti sold 300 shares of the firm’s stock in a transaction that occurred on Friday, October 25th. The stock was sold at an average price of $560.16, for a total value of $168,048.00. Following the sale, the executive vice president now owns 16,663 shares of the company’s stock, valued at approximately $9,333,946.08. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In related news, SVP Michael A. Boxer sold 2,000 shares of Thermo Fisher Scientific stock in a transaction dated Friday, October 25th. The shares were sold at an average price of $560.16, for a total value of $1,120,320.00. Following the sale, the senior vice president now directly owns 12,736 shares in the company, valued at $7,134,197.76. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Gianluca Pettiti sold 300 shares of the company’s stock in a transaction dated Friday, October 25th. The stock was sold at an average price of $560.16, for a total transaction of $168,048.00. Following the completion of the transaction, the executive vice president now owns 16,663 shares of the company’s stock, valued at approximately $9,333,946.08. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 12,300 shares of company stock valued at $6,831,268. 0.34% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

TMO has been the topic of a number of recent research reports. Evercore ISI reduced their price objective on Thermo Fisher Scientific from $630.00 to $620.00 and set an “outperform” rating on the stock in a research note on Thursday, October 24th. Robert W. Baird decreased their price target on Thermo Fisher Scientific from $632.00 to $622.00 and set an “outperform” rating for the company in a report on Thursday, October 24th. Stifel Nicolaus dropped their price objective on shares of Thermo Fisher Scientific from $680.00 to $665.00 and set a “buy” rating on the stock in a research note on Thursday, October 24th. Morgan Stanley raised their price target on shares of Thermo Fisher Scientific from $655.00 to $680.00 and gave the company an “overweight” rating in a report on Friday, September 20th. Finally, Raymond James boosted their price objective on shares of Thermo Fisher Scientific from $650.00 to $660.00 and gave the stock an “outperform” rating in a report on Thursday, July 25th. Four investment analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Thermo Fisher Scientific currently has an average rating of “Moderate Buy” and a consensus price target of $649.33.

Thermo Fisher Scientific Price Performance

Shares of NYSE TMO opened at $557.92 on Monday. The business has a 50 day simple moving average of $599.39 and a 200-day simple moving average of $583.76. Thermo Fisher Scientific Inc. has a twelve month low of $437.26 and a twelve month high of $627.88. The company has a market capitalization of $213.13 billion, a price-to-earnings ratio of 34.98, a price-to-earnings-growth ratio of 3.61 and a beta of 0.79. The company has a current ratio of 1.63, a quick ratio of 1.26 and a debt-to-equity ratio of 0.64.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings results on Wednesday, October 23rd. The medical research company reported $5.28 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.25 by $0.03. Thermo Fisher Scientific had a net margin of 14.48% and a return on equity of 17.49%. The company had revenue of $10.60 billion for the quarter, compared to the consensus estimate of $10.63 billion. During the same period last year, the firm posted $5.69 EPS. The company’s revenue for the quarter was up .2% on a year-over-year basis. As a group, equities research analysts expect that Thermo Fisher Scientific Inc. will post 21.68 earnings per share for the current year.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.